GNS Healthcare Blog

 This is the first of a series on the question of data availability, structure, value and challenges.

Biomarker-guided precision medicine is increasingly important in drug discovery and development. Pharma products that incorporate biomarkers to support optimized trial design and selection criteria are three times more likely to make it from Phase I to FDA approval than those  that do not.[1] Clinical trials that leverage biomarkers for patient stratification to guide their inclusion and exclusion criteria made up about 34% of oncology studies in 2017.[2] Clinical trials costs are also affected by biomarker-driven development. Equally impactful, one study notes that the use of a validated...